Lifestyle change program to help type 2 diabetes go into remission in Pakistan
Official title: EFFECTIVENESS OF A SIX-PILLAR LIFESTYLE MEDICINE INTERVENTION FOR TYPE 2 DIABETES REMISSION IN PAKISTANI CLINICAL SETTINGS: A RANDOMISED CONTROLLED TRIAL
Run by Green International University · NCT07912944 · Data updated 2026-11-12
This study tests whether a structured, plant-predominant lifestyle program can put adults with type 2 diabetes in Lahore, Pakistan into remission for the first six months.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Years to 65 Years |
| Sex | All |
| Enrollment | 178 (estimated) |
| Sponsor | Green International University Academic / other |
| Locations | 2 sites (Lahore, Punjab Province and 1 other locations) |
| Status | Recruiting |
| Started | September 26, 2026 |
| Main results expected | April 27, 2027 |
| Study ends | July 27, 2027 |
| Registry record updated | November 3, 2026 |
| Trial ID | NCT07912944 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 30–65 with type 2 diabetes managed on oral agents for up to 8 years and not on insulin, with BMI ≥23 kg/m2.
✕Probably not a fit
People with insulin-dependent diabetes, very long-standing diabetes beyond 8 years, or conditions that preclude participation may not benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In this randomized, parallel-group trial, adults with non-insulin-dependent type 2 diabetes in Lahore are assigned to a six-pillar lifestyle program or usual care. The program emphasizes a plant-predominant diet without counting calories, physical activity, adequate sleep, stress management, social connections, and reduced exposure to risky substances, delivered through Urdu sessions. Assessments occur at baseline, 3 months, and 6 months, with a primary goal of HbA1c below 6.5% sustained for at least three months without glucose-lowering medications. The study uses intention-to-treat analysis with 178 participants planned across two clinics, and follows a 6-month intervention with an exploratory 9-month follow-up.
Why it matters
Potential benefit: If successful, participants may achieve diabetes remission and reduced dependence on medications.
How similar studies have gone: Previous lifestyle approaches have shown potential for diabetes remission in similar populations, but this exact program and setting are relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 30-65 years * Confirmed diagnosis of type 2 diabetes * Non-insulin-dependent, managed on oral glucose-lowering agents only * Body mass index of 23 kg/m2 or above * Diabetes duration since diagnosis of up to 8 years (shorter duration: under 5 years; longer duration: 5 to 8 years) Exclusion Criteria: * Age below 30 or above 65 years * Insulin-dependent diabetes * Diabetes duration exceeding 8 years * Pregnancy or breastfeeding * Major psychiatric illness likely to impair participation or follow up Severe renal or hepatic impairment * Active malignancy * Bariatric surgery within the preceding 12 months * Inability to provide informed consent * Any other condition precluding safe participation in a structured lifestyle intervention.
Where it's running
-
Diabetic Clinic 1
Lahore, Punjab Province, Pakistan Recruiting -
Diabetic Clinic 2
Lahore, Punjab Province, Pakistan Recruiting
Study contacts
- Study coordinator: Sadaf Ayyaz, Pharm-D
- Email: sadafayyaz.sa@gmail.com
- Phone: 0092-333 4758491
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Colchicine for preventing cardiovascular disease in adults with type 2 diabetes
A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.
-
MWN105 injection in overweight or obese adults you may join
This early-phase trial tests whether MWN105 is safe and tolerable in overweight or obese adults in China, using a placebo comparison.
-
MWN109 tablets in adults with type 2 diabetes mellitus
A phase 2 trial tests MWN109 tablets versus placebo (and against active control semaglutide) to see if the medicine helps adults with type 2 diabetes lower their blood sugar.
-
Brain-heart axis in adults with type 2 diabetes
This study tests how brain activity and heart regulation relate to metabolic status in adults with type 2 diabetes to understand cognitive and functional health.
-
Digital dietary help for people on GLP-1 therapy to reach better blood sugar and weight
This trial tests whether adding a digital dietary program (NutriSteppe) to usual care helps adults on GLP-1 medications see better blood sugar control and weight results.
-
Cilostazol and Aspirin to Prevent Heart and Brain Events in Type 2 Diabetes
In people with type 2 diabetes and higher cardiovascular risk, researchers are testing whether taking cilostazol plus aspirin can help reduce major heart and brain events.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.